SOURCE: AVI BioPharma, Inc.

May 20, 2008 09:30 ET

AVI BioPharma to Present at TIDES Meeting

Presentation to Highlight AVI's Manipulation of Immune Response

PORTLAND, OR--(Marketwire - May 20, 2008) - AVI BioPharma, Inc. (NASDAQ: AVII) today announced that Patrick Iversen, Ph.D., AVI's Senior Vice President of Strategic Alliances, is presenting at the TIDES Oligonucleotide and Peptide Technology and Product Development meeting in Las Vegas on Tuesday, May 20, 2008. The title of his presentation is "Manipulating the Immune Response with Cell Penetrating Peptide Conjugated Phosphorodiamidate Morpholino Oligomers" and is to feature the targeting of genes, such as interleukin-10 (IL-10), involved in the host immune response, with AVI's proprietary Phosphorodiamidate Morpholino Oligomers and arginine-rich peptides. IL-10 is considered a key regulator of immune response to infection from viruses, bacteria and other organisms.

About AVI BioPharma

AVI BioPharma develops therapeutic products for the treatment of life-threatening diseases using third-generation NeuGene® antisense drugs and ESPRIT directed RNA alternative splicing technology. AVI's ESPRIT technology is initially being applied to potential treatments for Duchenne muscular dystrophy. AVI's NeuGene compounds are also designed to treat cardiovascular restenosis in stent and coronary artery bypass graft (CABG) procedures. In addition to targeting specific genes in the body, AVI's antiviral program uses NeuGene antisense compounds to combat disease by targeting single-stranded RNA viruses, including Marburg Musoke and Ebola Zaire viruses. More information about AVI is available at

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including, but not limited to, the results of research and development efforts, the results of preclinical and clinical testing, the effect of regulation by the FDA and other agencies, the impact of competitive products, product development, commercialization and technological difficulties, and other risks detailed in the company's Securities and Exchange Commission filings.

The information contained in this press release does not necessarily reflect the position or the policy of the Government and no official endorsement should be inferred.

Contact Information

  • AVI Press and Investor Contact:
    Michael Hubbard
    (Email Contact)
    Director of Corporate Communications
    (503) 227-0554